通过蛋白S和TFPIα-fVshort-protein S复合体抑制血栓的机制
ArXiv
|December 19, 2025
概括
蛋白S复合体 (PSC) 通过与血小板结合,强烈抑制血栓的产生. 它的度极大地调节出血和血栓性疾病,为血友病和V因子缺乏提供潜在的治疗点.
科学领域:
- 血液学 血液学 血液学
- 生物化学 生物化学
- 计算生物学 计算生物学
背景情况:
- 蛋白S (PS) 是一种参与出血和血栓性疾病的抗凝剂.
- PS增强了TFPI$α$的抗凝活性,与TFPI$α$和一个截断的因子V (fVshort) 形成了三分子复合体 (PSC).
- 对于PSC的精确抗凝剂机制尚不清楚.
研究的目的:
- 研究蛋白S复合体 (PSC) 在血液凝固中的抗凝剂作用.
- 阐明PSC如何影响血栓的产生及其对出血障碍的影响.
主要方法:
- 扩展了一种经过实验验证的血液凝结的数学模型.
- 血中包含的PSC和自由蛋白S (PS),以及血小板上的自由PS和TFPI$α$.
- 在各种条件下模拟的凝血动态,包括流量和特定的出血障碍.
主要成果:
- 在凝血开始后不久,PSC强烈抑制了血栓的产生.
- PSC与抑制Xa因子 (fXa) 的结合亲和力关键调节其抗凝作用.
- 在流动下,PSC会积聚在血小板上,并占据fV特定的结合点,限制fXa活动.
结论:
- 在PSC度的变化显著影响出血障碍的严重程度.
- 升高的PSC导致东德克萨斯州出血障碍的出血;降低的PSC在V因子缺乏症中挽救了血栓的产生.
- 阻断PSC的抗凝功能可能会改善严重血友病A的血栓生成.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.6K
Clot Retraction and Fibrinolysis
8.3K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
8.3K
Extrinsic and Intrinsic Pathways of Hemostasis
11.8K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
11.8K
Venous Thrombosis III: Interprofessional Care
262
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
262
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.0K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.0K
Protein-Drug Binding: Mechanism and Kinetics
1.6K
Protein-drug binding refers to the interaction between drugs and proteins within the body. This binding process can occur intracellularly, involving drug interactions with enzymes or receptors within cells, or extracellularly, involving plasma proteins in the blood.
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
1.6K


